Primary Sjögren’s Syndrome – A Complete Patient Guide

Overview

Primary Sjögren’s syndrome (pSS) is a chronic, systemic autoimmune disease in which the body’s immune system mistakenly attacks the moisture‑producing glands, particularly the salivary and lacrimal (tear) glands. This results in dry mouth and dry eyes, but the disease can also affect joints, kidneys, lungs, nerves, and blood vessels.

Who it affects

• Predominantly women – about 90 % of patients are female.
• Typical onset between the ages of 40 – 60, though it can occur in younger adults and, rarely, children.
• More common in people of European descent, but it occurs worldwide.

Prevalence

• Estimated 0.1 %–0.4 % of the general population have primary Sjögren’s syndrome, translating to roughly 1‑4 million adults in the United States.¹
• Among those referred to rheumatology clinics, up to 10 % are diagnosed with pSS.²

Symptoms

Symptoms can be “sicca” (dryness) or extra‑glandular, and they often fluctuate in intensity.

Dry‑Eye (Keratoconjunctivitis Sicca)

• Grittiness, burning, or a foreign‑body sensation.
• Redness, light sensitivity, and blurred vision.
• In severe cases, corneal ulcers or vision loss.

Dry‑Mouth (Xerostomia)

• Difficulty swallowing, speaking, or tasting food.
• Frequent dental cavities, oral infections, or fungal overgrowth (thrush).
• Swollen salivary glands, especially behind the jaw (parotid enlargement).

Other Common Symptoms

• Fatigue – often profound and disabling.
• Joint pain and stiffness, typically non‑erosive arthritis affecting hands, wrists, and knees.
• Muscle aches (myalgias).
• Skin dryness and rashes, especially on the trunk.
• Peripheral neuropathy – numbness, tingling, or burning sensations in hands/feet.
• Vaginal dryness leading to discomfort during intercourse.
• Chronic cough or hoarseness from dry throat.
• Dry nasal passages causing nosebleeds.

Less Common / Severe Manifestations

• Lymphoma (most often marginal‑zone B‑cell lymphoma) – risk is 5‑ to 10‑fold higher than the general population.³
• Kidney involvement (interstitial nephritis, tubular dysfunction).
• Interstitial lung disease.
• Vasculitis affecting skin, peripheral nerves, or organs.
• Raynaud’s phenomenon.

Causes and Risk Factors

Exactly why the immune system turns against moisture‑producing glands is unknown, but several factors appear to contribute.

Genetic predisposition

• Strong association with HLA‑DR and HLA‑DQ alleles (e.g., HLA‑DRB1*03:01).⁴
• Family clustering is modest; first‑degree relatives have a slightly increased risk.

Environmental triggers

• Viral infections (e.g., Epstein‑Barr virus, hepatitis C) have been implicated as possible initiators.
• Occupational exposure to silica dust is linked to higher incidence.

Hormonal influences

• The overwhelming female predominance suggests estrogen or other hormonal factors may modulate disease susceptibility.

Other risk factors

• Other autoimmune diseases – up to 30 % of patients have coexisting rheumatoid arthritis, systemic lupus erythematosus, or thyroiditis.
• Smoking – may exacerbate dryness but data on disease onset are mixed.

Diagnosis

Diagnosing primary Sjögren’s syndrome requires a combination of clinical assessment, objective testing, and exclusion of secondary causes.

Classification Criteria (2021 ACR/EULAR)

The American College of Rheumatology/European League Against Rheumatism criteria assign points to specific findings; a total score ≥ 4 confirms pSS.

1. Anti‑SSA/Ro antibodies (3 points)
2. Focus score ≥1 on labial salivary gland biopsy (3 points)
3. Ocular staining score ≥5 (or ≥4 with van Bijsterveld ≥1) (3 points)
4. Schirmer test ≤5 mm/5 min (1 point)
5. Unstimulated whole‑saliva flow ≤0.1 mL/min (1 point)

Key Diagnostic Tests

• Serology – ANA, anti‑SSA/Ro, anti‑SSB/La, rheumatoid factor, complement levels.
• Ophthalmologic evaluation – Schirmer test, tear‑film break‑up time, ocular surface staining with fluorescein or lissamine green.
• Salivary gland assessment – Unstimulated salivary flow measurement; sialography or salivary‑gland ultrasound for structural changes.
• Labial salivary gland biopsy – Presence of focal lymphocytic sialadenitis with a focus score ≥1 is highly specific.
• Imaging – Ultrasound of major salivary glands (non‑invasive) can detect hypoechoic areas suggestive of inflammation.

Differential Diagnosis

Conditions that can mimic the sicca symptoms include medication‑induced dry eye/mouth (anticholinergics, antihistamines), hepatitis C infection, sarcoidosis, graft‑versus‑host disease, and age‑related dryness.

Treatment Options

Therapy focuses on relieving symptoms, preserving gland function, and managing systemic involvement.

Symptomatic Relief

• Dry eyes
  • Artificial tears – preservative‑free drops used 4‑6 times daily.
  • Topical cyclosporine 0.05 % (Restasis) or lifitegrast 5 % (Xiidra) to increase tear production.
  • Punctal plugs – silicone or collagen plugs to block tear drainage.
• Dry mouth
  • Saliva substitutes (carboxymethylcellulose gels, mouthwashes).
  • Stimulating agents – pilocarpine 5 mg PO qid or cevimeline 30 mg PO tid (both cholinergic agonists).
  • Good oral hygiene – fluoride toothpaste, sugar‑free gum, regular dental check‑ups.

Systemic Immunomodulatory Therapy

Medication	Indication	Typical Dose	Key Side Effects
Hydroxychloroquine	Arthritis, fatigue, mild skin involvement	200‑400 mg PO daily	Retinal toxicity (annual eye exam), GI upset
Low‑dose glucocorticoids	Short‑term flare control	Prednisone 5‑10 mg PO daily (taper)	Weight gain, osteoporosis, glucose intolerance
Methotrexate	Persistent joint disease	7.5‑20 mg PO weekly + folic acid	Liver toxicity, marrow suppression
Azathioprine	Extra‑glandular disease (e.g., lung, kidney)	1‑2 mg/kg PO daily	Myelosuppression, hepatotoxicity
Biologic agents (Rituximab)	Severe systemic disease, refractory vasculitis, lymphoma‑like manifestations	1 g IV on day 1 and day 15, then every 6 months	Infusion reactions, infections, hepatitis reactivation

Management of Specific Organ Involvement

• Lymphoma surveillance – regular physical exams, imaging if lymphadenopathy or constitutional symptoms develop.
• Kidney involvement – ACE inhibitors/ARBs for proteinuria; nephrology referral.
• Pulmonary disease – high‑resolution CT scanning; consider immunosuppressants (mycophenolate, cyclophosphamide) if interstitial lung disease progresses.
• Neuropathy – gabapentin, duloxetine, or pregabalin; treat underlying inflammation with immunosuppression if indicated.

Lifestyle & Supportive Strategies

• Stay hydrated – sip water throughout the day.
• Use a humidifier at night to reduce mucosal drying.
• Avoid alcohol, caffeine, and tobacco, which exacerbate dryness.
• Chew sugar‑free gum or suck on lozenges to stimulate salivation.
• Protect eyes from wind, dust, and bright lights; wear sunglasses.
• Regular dental visits (every 6 months) for professional cleaning and fluoride treatment.

Living with Primary Sjögren’s Syndrome

While there is no cure, many people lead active, productive lives with appropriate management.

Daily Management Tips

1. Create a symptom diary – Track dryness levels, fatigue, and triggers to help your care team adjust therapy.
2. Oral health routine – Brush twice daily with fluoride toothpaste, floss, and use an antimicrobial mouth rinse (chlorhexidine) if plaque builds up.
3. Eye care regimen – Keep artificial tears on bedside; apply before sleep and upon waking.
4. Exercise – Low‑impact activities (walking, swimming, yoga) help combat fatigue and maintain joint flexibility.
5. Nutrition – Choose soft, moist foods; add sauces or gravies to make swallowing easier. Include omega‑3 fatty acids (fish, flaxseed) which may modestly reduce inflammation.
6. Sleep hygiene – Use a humidifier, elevate head, and maintain a regular bedtime to lessen night‑time dryness.
7. Support networks – Join patient organizations (e.g., Sjögren’s Foundation) for education, peer support, and research updates.

Monitoring & Follow‑up

• Every 6‑12 months: comprehensive labs (CBC, ESR/CRP, renal & liver panels, complement), serology, and assessment of glandular function.
• Annual ophthalmology visit with Schirmer test and retinal exam if on hydroxychloroquine.
• Dental exam every 6 months.
• Prompt evaluation of new systemic symptoms (e.g., unexplained weight loss, night sweats, persistent cough).

Prevention

Because primary Sjögren’s syndrome is autoimmune, it cannot be prevented in the traditional sense. However, certain measures may reduce the likelihood of severe disease or secondary complications:

• Maintain good oral and ocular hygiene to prevent infections and corneal damage.
• Avoid medications known to worsen dryness (e.g., antihistamines, tricyclic antidepressants) unless medically necessary.
• Stop smoking – it aggravates dryness and increases lymphoma risk.
• Control comorbid autoimmune conditions (e.g., treat thyroid disease) promptly.

Complications

If inadequately managed, pSS can lead to significant morbidity.

• Dental decay & oral infections – Up to 50 % develop new cavities within 5 years.⁵
• Corneal ulceration or perforation – May cause permanent vision loss.
• Lymphoma – Most common malignancy associated with pSS; usually marginal‑zone B‑cell type.
• Renal tubular acidosis – Can cause electrolyte abnormalities and kidney stones.
• Pulmonary fibrosis – Progressive shortness of breath.
• Neuropathy – May be disabling if not treated early.
• Pregnancy complications – Higher rates of pre‑eclampsia and preterm birth; close obstetric‑rheumatology collaboration is essential.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Sjögren syndrome.” Updated 2023. https://www.mayoclinic.org
2. Rheumatology International. “Epidemiology of primary Sjögren’s syndrome” 2022;42(6):987‑995.
3. U.S. National Cancer Institute. “Lymphoma Risk in Sjögren’s syndrome.” 2024. https://www.cancer.gov
4. Shen J, et al. “Genetic susceptibility loci for primary Sjögren’s syndrome.” *Nat Commun*. 2021;12:1024.
5. American Dental Association. “Oral health considerations for patients with Sjögren’s.” 2023. https://www.ada.org